Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

943
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

493
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Right Ventricular to Pulmonary Artery Uncoupling in Heart Failure With Multiple Valve Disease: Irreversible Fate or Opportunity To Intervene?

The Canadian journal of cardiology·2026
Same author

[Multimodality imaging in the diagnostic work-up in patients with heart failure in clinical practice].

Therapeutische Umschau. Revue therapeutique·2026
Same author

Genetic Cascade Screening for Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Serum Neurofilament Light Chain and Cardiovascular Outcomes in Patients With Atrial Fibrillation.

JAMA cardiology·2026
Same author

(Fully Automated) Free Wall Right Ventricular Longitudinal Strain in Transplant Patients: No Crystal Ball but Maybe Window to the Pulmonary Circulation.

The Canadian journal of cardiology·2026
Same author

Extraneurological Presentations of Tick-Borne Encephalitis Virus: A Rare Case of TBEV-Associated Myocarditis With Fever and Bicytopenia and a Systematic Literature Review.

Case reports in infectious diseases·2026

Related Experiment Video

Updated: May 3, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

31.4K

Complement factor concentrations in patients with acute myocardial infarction: time course and ability to predict

Roman Brenner1, Micha T Maeder, Lukas Trachsel

  • 1Division of Cardiology, Kantonsspital St. Gallen, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland.

Biomarkers in Medicine
|February 14, 2014
PubMed
Summary

Total hemolytic complement (CH50) levels at hospital admission may predict left ventricular (LV) dysfunction after myocardial infarction (MI). Higher CH50 indicates increased risk for developing LV dysfunction post-MI.

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K
Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.7K

Related Experiment Videos

Last Updated: May 3, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

31.4K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K
Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.7K

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Inflammatory processes are implicated in myocardial ischemia/reperfusion injury following myocardial infarction (MI).
  • Left ventricular (LV) dysfunction is a significant complication after MI, impacting patient prognosis.
  • Predictive biomarkers for post-MI LV dysfunction are crucial for timely intervention.

Purpose of the Study:

  • To investigate the predictive capability of complement factor concentrations for the development of LV dysfunction post-MI.
  • To assess the association between complement factors and C-reactive protein (CRP) with LV ejection fraction in acute MI patients.

Main Methods:

  • Fifty-five patients with acute myocardial infarction were enrolled.
  • Complement factors and CRP were measured at hospital admission (HA) and during the first 3 days.
  • LV ejection fraction was assessed via echocardiography before hospital discharge.

Main Results:

  • Elevated total hemolytic complement (CH50) at HA and peak CRP levels were observed in patients who developed LV dysfunction (LV ejection fraction ≤45%).
  • Individual complement factor concentrations or their temporal changes did not correlate with LV dysfunction occurrence.
  • CH50 concentration at HA independently predicted LV dysfunction.

Conclusions:

  • CH50 concentration at hospital admission may serve as a valuable biomarker for identifying acute MI patients at high risk of developing LV dysfunction.
  • This finding generates a hypothesis for further validation in larger cohorts.
  • Understanding the role of complement in MI pathophysiology can guide therapeutic strategies.